ELI Lilly has announced the results of its phase three trial into their Alzheimer's drug, donanemab.
According to a company press release, the trial showed that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer's disease.
The trial looked at how the drug altered a measure of cognition and ability to partake in activities of daily living, called the Alzheimer's Disease Rating Scale.
It found that for people with early stages of Alzheimer's, there was a 35% slowing of decline on this scale.
The study's investigator, Prof Bruce J Brew, a consultant physician and neurologist at UNSW was "very encouraged by the study's results for patients with Alzheimer's disease".
"While the full results are yet to be published, the data that has been released shows it significantly slows progression of Alzheimer's.
"The drug met all primary and secondary endpoints, however, it is definitely not a cure for Alzheimer's," Brew asserted.
"Nonetheless, it slows the inevitable worsening of the disease allowing patients more quality time with loved ones.
"The drug acts in a similar way to other amyloid monocloncal antibodies and is associated with a similar small risk of cerebral microhaemorrhages and oedema, and it is hoped that the drug will be available in the near future," Brew concluded.
The above article was sent to subscribers in Pharmacy Daily's issue from 08 May 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 08 May 23
